Disease · EFO_0009869

xerostomia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. xerostomia. Diseases, record EFO_0009869. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009869

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: xerostomia; Open Targets
Open Targets ID: EFO_0009869; Open Targets
Other names: dry mouth; Open Targets
MeSH: D014987; MeSH
Highest stage of its drugs: Approval, for 3 of its 26 drugs, from DailyMed; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PILOCARPINE	CHEMBL550	Small molecule	Approval	DailyMed	7	6	6	Drugs and targets
AMIFOSTINE	CHEMBL1006	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
CEVIMELINE HYDROCHLORIDE	CHEMBL2218917	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CEVIMELINE	CHEMBL168815	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALOE	CHEMBL2108221		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BETAINE	CHEMBL95889	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HONEY	CHEMBL2108391		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
LACTOFERRIN, BOVINE	CHEMBL5095320		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
MYELOPEROXIDASE	CHEMBL2107858	Enzyme	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
POVIDONE	CHEMBL2108139		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets24

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CHRM1	Muscarinic acetylcholine receptor M1	3	Muscarinic acetylcholine receptor M1 agonist	Approval	https://conductscience.org/library/genes/1128	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	3	Muscarinic acetylcholine receptor M3 agonist	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
ACHE	Acetylcholinesterase	1	Acetylcholinesterase inhibitor	Phase 2	https://conductscience.org/library/genes/43	Drugs and targets
BHMT	Betaine-homocysteine S-methyltransferase	1	Betaine-homocysteine S-methyltransferase substrate	Phase 3	https://conductscience.org/library/genes/635	Drugs and targets
BHMT2	Betaine-homocysteine S-methyltransferase	1	Betaine-homocysteine S-methyltransferase substrate	Phase 3	https://conductscience.org/library/genes/23743	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
RBX1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/9978	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets

1 to 10 of 24

See all 24 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00656513	Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Phase 2/3	196	2017-08-21	Head and Neck Cancer, Xerostomia	PILOCARPINE	Its record names the disease	ClinicalTrials.gov
NCT01652001	Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity	Phase 2/3	185	2016-04-05	Xerostomia, Depression, Hypertension	MALIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00233363	Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome	Phase 2	104	2021-06-04	Xerostomia, Sjogren's Syndrome	REBAMIPIDE	Its record names the disease	ClinicalTrials.gov
NCT04239872	Fluoride Retention in the Mouth of Older Adults	Phase 1	20	2022-06-21	Hyposalivation	CALCIUM, FLUORIDE	Its record names the disease	ClinicalTrials.gov
NCT01690052	Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva	Not applicable	15	2014-08-06	Dry Mouth	CEVIMELINE, PILOCARPINE	Its record names the disease	ClinicalTrials.gov
NCT00852839	A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome	Phase 2	140		Dry Mouth Associated With Sjogren's Syndrome, Xerostomia	552-02	Its record names the disease	ClinicalTrials.gov
NCT05506137	Xerostomia in Patients With a Life-limiting Condition or Frailty	Phase 3	120		Xerostomia, Dry Mouth	PILOCARPINE	Its record names the disease	ClinicalTrials.gov
NCT02982577	Effect of Pilocarpine in Patients With Xerostomia	Phase 4	80		Xerostomia	PILOCARPINE	Its record names the disease	ClinicalTrials.gov
NCT01627626	Effect of 0.1% Pilocarpine Mouthwash on Xerostomia	Not applicable	60		Xerostomia	PILOCARPINE	Its record names the disease	ClinicalTrials.gov
NCT00095927	Randomized Amifostine For SCCHN	Phase 2	58		Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia	AMIFOSTINE, CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Malic Acid 1% vs Control: serious adverse events	0 of 100	0 of 85	185	NCT01652001	Trial comparisons
Rebamipide vs Placebo: deaths from any cause	0 of 53	0 of 51	104	NCT00233363	Trial comparisons
Rebamipide vs Placebo: serious adverse events	1 of 53	1 of 51	104	NCT00233363	Trial comparisons
Fluoride Mouthwash vs Calcium Mouthwash Before Fluoride Mouthwash: deaths from any cause	0 of 19	0 of 20	39	NCT04239872	Trial comparisons
Fluoride Mouthwash vs Calcium Mouthwash Before Fluoride Mouthwash: serious adverse events	0 of 19	0 of 20	39	NCT04239872	Trial comparisons
Cevimeline Then Pilocarpine (Intervention 1) vs Pilocarpine Then Cevimeline (Intervention 2): deaths from any cause	0 of 12	0 of 12	24	NCT01690052	Trial comparisons
Cevimeline Then Pilocarpine (Intervention 1) vs Pilocarpine Then Cevimeline (Intervention 2): serious adverse events	0 of 12	0 of 12	24	NCT01690052	Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29432648	RESULT	1	PubMed
27767109	RESULT	1	PubMed
26867879	RESULT	1	PubMed
26563850	RESULT	1	PubMed
26065354	RESULT	1	PubMed
26001395	RESULT	1	PubMed
25841622	RESULT	1	PubMed
25639487	RESULT	1	PubMed
25065774	RESULT	1	PubMed
24692737	RESULT	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009869

GET https://conductscience.org/api/diseases/v1/EFO_0009869/drugs?page=2

API reference For AI assistants